Immuno-Oncology 2014: Sponsors
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.
Display no. 3
F. Hoffmann-La Roche Ltd.
1 Grenzacherstrasse 124
Tel: +41 61 688 11 11
Fax: +41 61 691 93 91
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
All trademarks used or mentioned in this release are protected by law.
Today's MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well.
Display no. 5
NW Bio is developing DCVax® autologous dendritic cell vaccines for solid tumors. The Company’s DCVax-L® for resectable tumors is in a 348-patient Phase III trial in the US and Europe for newly-diagnosed Glioblastoma multiforme, and recently reported encouraging data on 55 “Information Arm” patients who were ineligible for the trial. DCVax-Direct® is in a 60-patient Phase I/II trial for all types of inoperable solid tumors.
Display no. 2